FDA gives priority review to Loxo-Bayer cancer treatment

May 29, 2018

A new cancer drug will be set on the fast track to approval by the FDA. 

The medication, larotrectinib, is being developed through a collaboration between Loxo Oncology and Bayer AG. According to Reuters, analysts anticipate that annual sales for the drug could range between $500 million and $1 billion.  

Larotrectinib is being developed to target a wide array of tumors. The FDA granted priority review for the drug to treat patients with tumors that have a neurotrophic tyrosine receptor kinase gene mutation.

The FDA has set an action target date of Nov. 26. 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments